Xeljanz (tofacitinib)

Manufacturer:

Pfizer

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

Manufacturer Website

phone:

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers
treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers
treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers
treatment of adult patients with moderately-to-severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers
treatment of active polyarticular course juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers

Conditions:

Atopic Dermatitis
Ankylosing Spondylitis
Crohn’s Disease
Juvenile Idiopathic Arthritis
Non-Radiographic Axial Spondyloarthritis
Psoriatic Arthritis
Rheumatoid Arthritis
Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology